Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

@article{Black1996RandomisedTO,
  title={Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures},
  author={Dennis M Black and Steven R. Cummings and David Brian Karpf and Jane A. Cauley and Desmond E Thompson and Michael C. Nevitt and Doug C. Bauer and Harry K. Genant and William L. Haskell and R Marcus and Susan M. Ott and James C. Torner and Sara A. Quandt and Theodore F. Reiss and Kristine E. Ensrud},
  journal={The Lancet},
  year={1996},
  volume={348},
  pages={1535-1541}
}
BACKGROUND Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone mass. METHODS Women aged 55-81 with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing… Expand

Paper Mentions

Observational Clinical Trial
The study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. The study will contribute with new knowledge about biochemical markers of bone… Expand
ConditionsOsteoporosis
InterventionDrug
Interventional Clinical Trial
This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density… Expand
ConditionsBreast Neoplasms
InterventionDrug, Procedure, Radiation
Interventional Clinical Trial
This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT). Participants in the FLEX study were randomly… Expand
ConditionsOsteoporosis, Postmenopausal
InterventionDrug
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
TLDR
Alendronate effectively reduces fracture risk in postmenopausal women with vertebral fractures and low BMD, including those women at highest risk because of advanced age or severe osteoporosis. Expand
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
TLDR
In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity. Expand
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.
TLDR
In women with low bone mass who do not meet the bone mineral density criterion for osteoporosis, alendronate is effective in reducing the risk of vertebral fractures. Expand
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial
TLDR
Among patients who adhere to treatment with alendronate, even those who lose BMD benefit from a substantial reduction in risk of vertebral fracture, and the reduction in bone turnover induced by alendronsate might be more important than BMD changes. Expand
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
TLDR
Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease. Expand
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
TLDR
Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures, suggesting that, among women taking antiresorptive agents, greater increases in B MD are associated with lower risk of new fractures. Expand
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
TLDR
Reductions in fracture risk during treatment with alendronate are consistent in women with existing vertebral fractures and those without such fractures but with bone mineral density in the osteoporotic range. Expand
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial
  • A. Schwartz, D. Bauer, +8 authors D. Black
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2010
TLDR
Continuing ALN for 10 years instead of stopping after 5 years reduces NVF risk in women without prevalent vertebral fracture but does not reduce risk of NVF in women whose T‐scores are greater than −2.5 or less. Expand
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
TLDR
Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture, and these results highlight the consistent antifracture efficacy of denosumAB in patients with varying degrees of fracture risk. Expand
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
TLDR
There was insufficient power to compare the fracture risks between alendronate and raloxifene, and the only adverse events with an incidence that differed between groups were colonoscopy, diarrhea, and nausea. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
TLDR
Etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures. Expand
Pre-existing fractures and bone mass predict vertebral fracture incidence in women.
TLDR
Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone and Physicians can use these risk factors to identify patients at greatest risk for new fractures. Expand
Treatment of postmenopausal osteoporosis with transdermal estrogen.
TLDR
Transdermal estradiol treatment is effective in postmenopausal women with established osteoporosis and vertebral fractures and Histomorphometric evaluation of iliac biopsy samples confirmed the effect of estrogen on bone formation rate per bone volume. Expand
Risk of hip fracture in women with vertebral fracture
TLDR
Data from a population‐based retrospective cohort study on Rochester women who were first diagnosed with one or more vertebral fractures in 1950–1979 are consistent with heterogeneity in the pathogenesis of different osteoporotic fractures. Expand
Treatment of postmenopausal osteoporosis with calcitriol or calcium
TLDR
Women who received calcitriol had a significant reduction in the rate of new vertebral fractures during the second and third years of treatment, as compared with the women who received calcium. Expand
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
TLDR
It is suggested that, compared with calcium alone, salcatonin given intranasally reduces the rates of fracture by two thirds in elderly women with moderate osteoporosis and increases spinal bone mass in a dose dependent manner. Expand
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
TLDR
A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis. Expand
Epidemiology of vertebral fractures in women.
TLDR
Vertebral fracture prevalence was assessed in an age-stratified random sample of Rochester, Minnesota women aged 50 years and over, finding that vertebral fractures were common and increased with age. Expand
Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures
  • D. Black, L. Palermo, +4 authors S. Cummings
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1995
TLDR
It is concluded that use of any of the similar methods, with or without triage, provides a valid approach to defining vertebral deformities. Expand
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.
TLDR
The combination of calcium fluoride, and estrogen was more effective than any other combination and grounds for optimism about the efficacy of combinations of available agents with sodium fluoride for fracture in postmenopausal osteoporosis. Expand
...
1
2
3
...